Work

A harmonized approach towards immuno-monitoring of myeloid-derived suppressor cells for prediction of clinical outcomes in melanoma patients treated with ipilimumab

Year: 2015
Type: article
Abstract: Ipilimumab is a monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) that belongs to a new class of immunotherapeutic drugs called immune checkpoint inhibitors (ICI) which prevent the feedback inhibition of activated T cells and hold great promise to treat cancer. Indeed, it has been demonstrated that ipilimumab increases overall survival (OS) of metastatic melanoma patients, but a durable 5-year survival benefit is observed in a proportion of patients ranging from 12% to 49% and, the treatment has mild to severe immune-related adverse events (irADR). In this context, the development of reliable biomarkers is of great importance to select patients with higher possibility to benefit from this treatment. In this respect, immune profiling could play a significant role, and, in particular, the monitoring of myeloid-derived suppressor cells (MDSC), which are predictive of OS and response to chemotherapy in many types of cancer, and thus represent a promising biomarker also for response to ICI. However, the validation of the predictive significance of MDSCs is challenged by the phenotypic complexity of these cells, that lacks an international consensus on the minimal requirements for MDSC monitoring. To meet this request, we organised the first proficiency panel to harmonize human MDSC phenotyping in collaboration with the Cancer Immunoguiding Program. Hence, we proceeded to the first phase, that consisted in phenotyping three batches of PBMC distributed to the 23 participating laboratories. We also analysed data from the 23 laboratories and observed that the quantification of MDSCs across different laboratories was affected by high variance, and we identified some parameters responsible for the high heterogeneity of results. Results of this first step will set the basis for the second step which is expected to reduce inter-laboratory variance. From this experience, we developed a standardized approach to monitor the circulating levels of four MDSC subsets in melanoma patients undergoing ipilimumab treatment. These results were included in a wide dataset together with other tumor-associated and immunological parameters (TIPs) and used to identify early predictors of OS and toxicity through a multivariate non-parametric statistical approach. We followed the variations of TIPs during ipilimumab treatment and identified two immune profiles predictive of OS. The immune profile of patients with better prognosis included: lower baseline levels of IL-6, CRP and VEGF and higher post-treatment frequencies of CD3+ T cells and CD4+/CD279+ T cells. On the other hand, patients with worse prognosis presented higher post-treatment levels of MDSC1 and 2 and of CD8+/PD-1+ T cells. In addition, the development of grade 3 irADR was negatively associated to the levels of CD3+ and CD4+/PD-1+ T cells and of eosinophils, while positively associated to an increased variance of MDSC4. In conclusion, we demonstrated that the monitoring of the immunological correlates has the potential to identify patients with better prognosis following ipilimumab treatment, thus guiding a more rational use of this therapy
Author: Vera Damuzzo
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W2273897152
FWCI:
Cites: 106
Cited by:
Related to: 10